Literature DB >> 30190949

Who should undergo liver transplantation for hepatocellular carcinoma? Ablate, wait … and see!

Willscott E Naugler1,1, Barry Schlansky1,1, Susan L Orloff2,2.   

Abstract

Entities:  

Year:  2014        PMID： 30190949      PMCID： PMC6095151          DOI： 10.2217/hep.14.2

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN： 2045-0923


× No keyword cloud information.
  22 in total

1.  Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.

Authors:  David Goldberg; Benjamin French; Peter Abt; Sandy Feng; Andrew M Cameron
Journal:  Liver Transpl       Date:  2012-04       Impact factor: 5.799

2.  Principles for allocation of scarce medical interventions.

Authors:  Govind Persad; Alan Wertheimer; Ezekiel J Emanuel
Journal:  Lancet       Date:  2009-01-31       Impact factor: 79.321

3.  Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system.

Authors:  K Washburn; E Edwards; A Harper; R Freeman
Journal:  Am J Transplant       Date:  2010-05-10       Impact factor: 8.086

Review 4.  Development of the allocation system for deceased donor liver transplantation.

Authors:  John M Coombes; James F Trotter
Journal:  Clin Med Res       Date:  2005-05

5.  Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma.

Authors:  Gerd Otto; Sascha Herber; Michael Heise; Ansgar W Lohse; Christian Mönch; Fernando Bittinger; Maria Hoppe-Lotichius; Marcus Schuchmann; Anja Victor; Michael Pitton
Journal:  Liver Transpl       Date:  2006-08       Impact factor: 5.799

6.  Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.

Authors:  Neil Mehta; Jennifer L Dodge; Aparna Goel; John Paul Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Liver Transpl       Date:  2013-12       Impact factor: 5.799

7.  Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.

Authors:  Francis Y Yao; Robert K Kerlan; Ryutaro Hirose; Timothy J Davern; Nathan M Bass; Sandy Feng; Marion Peters; Norah Terrault; Chris E Freise; Nancy L Ascher; John P Roberts
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

8.  Liver transplantation for hepatocellular carcinoma: the MELD impact.

Authors:  Pratima Sharma; Vijayan Balan; Jose L Hernandez; Ann M Harper; Erick B Edwards; Hector Rodriguez-Luna; Thomas Byrne; Hugo E Vargas; David Mulligan; Jorge Rakela; Russell H Wiesner
Journal:  Liver Transpl       Date:  2004-01       Impact factor: 5.799

9.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Authors:  Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

10.  Survival benefit-based deceased-donor liver allocation.

Authors:  D E Schaubel; M K Guidinger; S W Biggins; J D Kalbfleisch; E A Pomfret; P Sharma; R M Merion
Journal:  Am J Transplant       Date:  2009-04       Impact factor: 8.086
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.